Delivered a successful investor pitch to drive global expansion and advance licensing, joint research, and strategic partnerships.
DigmBio at BIO International Convention 2025
Identified strong interest from pharmaceutical companies in DM3159 and explored potential future collaborations, including licensing, co-development, and joint research, following U.S. FDA approval.
DigmBio at BIO Korea 2025
Discussions on clinical progress and future partnerships for Digmbio's pipeline with global pharmaceutical companies were held at BIO Korea 2025.
With Dr. Zinnia Xu, ORIC Pharmaceuticals
DigmBio at Bio International Convention 2024
During the 2024 Bio International Convention in San Diego, Digmbio engaged in discussions about business partnerships and collaborations with international pharmaceutical companies.
DigmBio at BioKorea 2024
DigmBio showcased its innovative pipeline at Bio Korea 2024.